Investors Spar Over Damages In Valeant, Pershing Rows
Investors behind two suits accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. duked it out...To view the full article, register now.
Already a subscriber? Click here to view full article